Tamer Fandy, Ph.D.



Postdoctoral Research Fellow, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Ph.D., School of Pharmacy, Department of Pharmaceutical Sciences, University of Maryland at Baltimore
M.S., Department of Pharmaceutical Sciences, University of Southern California

Research Interests

Epigenetics is defined as any heritable changes in gene expression that do not involve a change in the DNA sequence. These changes can be mediated through DNA methylation, histone modifications and microRNAs (miRNAs). My laboratory is involved in both basic and translational research in the field of molecular epigenetics. Specifically, we are interested in understanding the mechanisms of action of the DNA methyltransferase (DNMT) inhibitors and how they induce clinical remission in hematological malignancies. Although they are FDA- approved, there are several unknown questions about DNMT inhibitors; for instance, can we predict who will respond to the drugs? Can we make the therapy more effective? Do they work by reversing DNA methylation or by other mechanisms? 

Another area of interest is monitoring the epigenetic changes associated with the use of dietary agents like curcumin and its more stable analogues. Curcumin is a promising chemopreventive agent and demonstrated anticancer effect in different tumors. Understanding the impact of curcumin on the epigenome can explain the mechanism by which curcumin contributes to cancer prevention and treatment. The use of curcumin in combination with other epigenetic modifiers is largely undiscovered and we are interested in studying the interactive effects of curcumin with these drugs.

Selected Publications and Invited Reviews

Chahin H, Ekong B, Fandy TE (2013). Epigenetic therapy in malignant and chronic diseases. J Pharmacogenom Pharmacoproteomics 4: 118.

Fandy TE (2012). The sequential combination paradigm in epigenetic therapy. J Pharmacogenom Pharmacoproteomics 3: e124. doi:10.4172/21530645.1000e124.

Fandy TE, Gore SD (2010). Epigenetic targets in human neoplasms. Epigenomics 2(2): 221-232.

Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. (2009). Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114(13): 2764-2773.

Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114(16): 3448-3458.

Fandy TE (2009). Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 16(17): 2075-2085.

Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, et al. (2008). p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27(25): 3615-3623.

Fandy TE, Shankar S, Srivastava RK (2008). Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 7: 60.

Fandy TE, Carraway H, Gore SD (2007a). DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 13(1): 40-48.

Fandy TE, Ross DD, Gore SD, Srivastava RK (2007b). Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. Cancer Chemother Pharmacol 60(3): 313-319.

Fandy TE, Srivastava RK (2006). Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol 58(4): 471-477.

Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, et al. (2006). IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 5(2): 457-466.

Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005). Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7(7): 646-657.

Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK (2005). Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16(6): 1125-1138.

Kim KJ, Fandy TE, Lee VH, Ann DK, Borok Z, Crandall ED (2004). Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 287(3): L616-622.

Lee VH, Sporty JL, Fandy TE (2001). Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv Drug Deliv Rev 50 Suppl 1: S33-40.  

Book Chapters

Tamer E. Fandy, Hetty Carraway, Steven D. Gore. Modulating gene expression as a therapeutic approach in the treatment of acute myeloid leukemia (AML). In Acute Myelogenous Leukemia, edited by J. Karp, Humana Press, chapter 13, 273-289, 2007.

Assistant Professor
Department of Pharmaceutical Sciences - Vermont Campus